Novartis Buys Myricx Bio for Up to $1.5 Billion to Add Experimental Cancer Drug

3 articles · Updated · Bloomberg · Jul 6

$1.1 billion upfront and up to $400 million in milestones will give Novartis control of British biotech Myricx Bio, the company said Monday.
The deal adds an experimental cancer medicine aimed at delivering more potent treatment directly to tumors while limiting damage to healthy cells.
For Novartis, the acquisition strengthens its oncology pipeline through a targeted-drug approach designed to improve efficacy and reduce side effects.

Sources

Left50%

Center33%

Right17%

Bloomberg6h ago

Novartis to Acquire Myricx Bio for Up to $1.5 Billion for Cancer Drug

The Wall Street Journal6h ago

Novartis to Buy Myricx Bio for Up to $1.5 Billion - WSJ

Malone Telegram12h ago

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform | Press Releases | mymalonetelegram.com

9 Sources

Can a novel cancer drug platform justify a $1.5 billion price before human trials even begin?

Is Big Pharma's M&A frenzy a true innovation engine or a high-stakes bubble destined to burst?

Novartis Acquires Myricx Bio for $1.5 Billion: Pioneering NMTi ADCs to Transform Oncology Pipeline

Overview

Novartis has agreed to acquire Myricx Bio, a British biotech company, in a deal announced on July 6, 2026. This acquisition, valued at up to USD 1.5 billion with an upfront payment of USD 1.1 billion, marks a major expansion of Novartis’s oncology pipeline. The deal is set to strengthen Novartis’s ability to develop advanced cancer treatments, especially in Antibody-Drug Conjugates (ADCs). Myricx Bio’s innovative platform of active ingredients is seen as potentially groundbreaking, and the acquisition aligns with Novartis’s strategic growth plans, with the transaction expected to close in the second half of 2026.

...